Calidi Biotherapeutics, Inc. (CLDI)
- Previous Close
0.1600 - Open
0.1622 - Bid 0.1624 x 900
- Ask 0.1650 x 1200
- Day's Range
0.1543 - 0.1670 - 52 Week Range
0.1440 - 13.7900 - Volume
885,124 - Avg. Volume
672,993 - Market Cap (intraday)
7.868M - Beta (5Y Monthly) 0.25
- PE Ratio (TTM)
-- - EPS (TTM)
-1.7300 - Earnings Date --
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
7.75
Calidi Biotherapeutics, Inc., a clinical stage immuno-oncology company, engages in developing allogeneic stem cell-based platforms to potentiate and deliver oncolytic viruses to cancer patients in the United States. Its product pipeline comprising CLD-101, which is in phase 1b clinical trial for the treatment of high grade glioma; CLD-101, which is in phase 1 clinical trial for the treatment of recurrent high grade glioma; CLD-201, which is in preclinical trial for the treatment of advanced solid tumors, such as triple-negative breast cancer, metastatic/unresectable melanoma, head and neck squamous cell carcinoma, advanced soft tissue sarcoma, and advanced basal cell carcinoma; and CLD-400, which is in preclinical trial for the treatment of lung cancer and metastatic solid tumors. The company offers NeuroNova platform and SuperNova platform. The company is headquartered in San Diego, California.
www.calidibio.comRecent News: CLDI
Performance Overview: CLDI
Trailing total returns as of 4/26/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: CLDI
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: CLDI
Valuation Measures
Market Cap
7.87M
Enterprise Value
13.15M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
50.83
Price/Book (mrq)
--
Enterprise Value/Revenue
49.42
Enterprise Value/EBITDA
-0.49
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-287.25%
Return on Equity (ttm)
--
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-29.22M
Diluted EPS (ttm)
-1.7300
Balance Sheet and Cash Flow
Total Cash (mrq)
1.95M
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
-43.96M